Could high levels of cell-free DNA in maternal blood be associated with maternal health and perinatal outcomes?

Atakul, Bahar Konuralp; Koç, Altuğ; Adiyaman, Duygu; Kuyucu, Melda; Yıldırım, Alkım Gülşah Şahingöz; Güvenç, Merve Saka; Erdoğan, Kadri Murat; Sengul, Baris; Öztekin, Deniz

doi:10.1080/01443615.2019.1671324

Cited by 3 publications

(10 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Four focused on the cfDNA level variation in pregnant women with obesity and normal body weight with the aims to examine the effects of abnormal maternal weight on cfDNA levels of the mothers and fetus (Figure 2). 31,37,41,44 …”

Section: Resultsmentioning

confidence: 99%

“…Of the 11 articles screened out from our search, four studies were found to focus on investigating the influence of maternal obesity on cfDNA levels in the pregnant women 31,37,41,44 . However, varying results were observed.…”

Section: Resultsmentioning

confidence: 99%

“…Of the 11 articles screened out from our search, four studies were found to focus on investigating the influence of maternal obesity on cfDNA levels in the pregnant women. 31,37,41,44 However, varying results were observed. While two cohorts (one from United States 31 and one from Germany 41 ) both reported a significant positive correlation between total cfDNA level and maternal BMI during pregnancy, the other two studies had opposite observation.…”

Section: Association Between Gestational Obesity and Maternal And Fet...mentioning

confidence: 99%

“…36,40,42 Four focused on the cfDNA level variation in pregnant women with obesity and normal body weight with the aims to examine the effects of abnormal maternal weight on cfDNA levels of the mothers and fetus (Figure 2). 31,37,41,44 Sample size of the included studies ranged from 14 to 2817 with 3 out of the 11 articles specified subjects' ethnicity (Finnish, Danish, and Iranian). Six articles had recruited gender-specific subjects (100% male or female) for the study, and all the articles with 100% female subjects focused on pregnant women.…”

Section: Study Characteristics and Qualitymentioning

confidence: 99%

See 3 more Smart Citations

A systematic review on the applicability of cell‐free DNA level as an obesity biomarker

Tung,

Tsang,

Ngo

et al. 2024

Obesity Reviews

View full text Add to dashboard Cite

SummaryObesity has become a global health concern in recent decades. Utilizing biomarkers presents a promising approach to comprehensively monitor the progress of obesity and its associated health conditions. This review aims to synthesize the available evidence on the correlation between cfDNA level and obesity and to provide insights into the applicability of using cfDNA level as a tool for monitoring progression of obesity. Searches were performed in PubMed and Embase on April 1, 2022. Data and other relevant information were extracted and compiled into a structured table for further analysis. Among 1170 articles screened, 11 articles were included in this review and assessed qualitatively. The results demonstrated that existing evidence mainly focused on three populations, including healthy individuals, cancer patients and pregnant women. Majority of the studies on healthy individuals identified a significant association between cfDNA level and body weight status but not among cancer patients. Varying results were observed among pregnant women at different gestational trimesters. Our review summarized some preliminary evidence on the association between cfDNA level and obesity. More cohort studies in larger scale with comprehensive assessment have to be conducted to examine the applicability of cfDNA as a biomarker for severity and disease progression of obesity.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Association Between Gestational Obesity and Maternal And Fet...mentioning

confidence: 99%

Section: Study Characteristics and Qualitymentioning

confidence: 99%

See 2 more Smart Citations

A systematic review on the applicability of cell‐free DNA level as an obesity biomarker

Tung,

Tsang,

Ngo

et al. 2024

Obesity Reviews

View full text Add to dashboard Cite

show abstract

“…In cases of advanced cancers [ 18 , 19 , 20 ], autoimmune [ 21 , 22 , 23 , 24 , 25 ], inflammatory [ 26 ], traumatic [ 27 , 28 ], post-transplantation [ 29 ] or infectious diseases [ 30 , 31 ] usually a more increased amount is detected. In addition, cfDNA levels could also be increased, due to vigorous physical exertion (such as intense sports, e.g., half marathon, ultramarathon, TRX exercises) [ 32 , 33 ] and pregnancy [ 34 ]. Fetal cfDNA, which is primarily produced by placental trophoblast cells during pregnancy [ 35 ], is detected in the maternal circulation, as early as in the first trimester, accounting for 10 to 15% of the total cfDNA concentration [ 36 ].…”

Section: Origin Release Amount and Clearance Of Cell-free Dnamentioning

confidence: 99%

Cell-Free DNA in the Pathogenesis and Therapy of Non-Infectious Inflammations and Tumors

Műzes¹,

Barta²,

Szabó³

et al. 2022

Biomedicines

View full text Add to dashboard Cite

The basic function of the immune system is the protection of the host against infections, along with the preservation of the individual antigenic identity. The process of self-tolerance covers the discrimination between self and foreign antigens, including proteins, nucleic acids, and larger molecules. Consequently, a broken immunological self-tolerance results in the development of autoimmune or autoinflammatory disorders. Immunocompetent cells express pattern-recognition receptors on their cell membrane and cytoplasm. The majority of endogenous DNA is located intracellularly within nuclei and mitochondria. However, extracellular, cell-free DNA (cfDNA) can also be detected in a variety of diseases, such as autoimmune disorders and malignancies, which has sparked interest in using cfDNA as a possible biomarker. In recent years, the widespread use of liquid biopsies and the increasing demand for screening, as well as monitoring disease activity and therapy response, have enabled the revival of cfDNA research. The majority of studies have mainly focused on the function of cfDNA as a biomarker. However, research regarding the immunological consequences of cfDNA, such as its potential immunomodulatory or therapeutic benefits, is still in its infancy. This article discusses the involvement of various DNA-sensing receptors (e.g., absent in melanoma-2; Toll-like receptor 9; cyclic GMP–AMP synthase/activator of interferon genes) in identifying host cfDNA as a potent danger-associated molecular pattern. Furthermore, we aim to summarize the results of the experimental studies that we recently performed and highlight the immunomodulatory capacity of cfDNA, and thus, the potential for possible therapeutic consideration.

show abstract

Identifying risk of stillbirth using machine learning

Cersonsky¹,

Ayala²,

Pınar³

et al. 2023

American Journal of Obstetrics and Gynecology

View full text Add to dashboard Cite

Could high levels of cell-free DNA in maternal blood be associated with maternal health and perinatal outcomes?

Cited by 3 publications

References 27 publications

A systematic review on the applicability of cell‐free DNA level as an obesity biomarker

A systematic review on the applicability of cell‐free DNA level as an obesity biomarker

Cell-Free DNA in the Pathogenesis and Therapy of Non-Infectious Inflammations and Tumors

Identifying risk of stillbirth using machine learning

Contact Info

Product

Resources

About